Striatal MPP+ levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice

Neurodegeneration

Volumn 5, Issue 2, 1996, Pages 129-136

  Vaglini, Francesca ^a,b   Fascetti, Flavia ^c   Tedeschi, Daniele ^c   Cavalletti, Micaela ^c   Fornai, Francesco ^c   Corsini, Giovanni U ^c  

^a Associazione 'Anni Verdi'   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c NONE

Author keywords

Dopamine; MPP+; MPTP; Neurotoxicity; Nicotine

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETALDEHYDE; CLONIDINE; DIZOCILPINE; DOPAMINE; NICOTINE; SELEGILINE; VANOXERINE; ZALCITABINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030175359     PISSN: 10558330     EISSN: None     Source Type: Journal    
DOI: 10.1006/neur.1996.0019     Document Type: Article

References (42)

1. Aizenmann E, Tang LH, Reynolds IJ (1991) Effects of nicotinic agonists on the NMDA receptor. Brain Res 551:355-357
2. Andén NE., Grabowska M (1976) Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain Eur J Pharmacol 39:275-282
3. Behmand RA, Harik SI (1992) Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. J Neurochem 58:776-779
4. Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120:574-578
5. Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jacobowitz DM, Kopin IJ (1984) Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), in rat, guinea pig and monkey. Psychopharmacol Bull 20:548-553
6. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD (1984) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106:209-210
7. Cleeter MW, Cooper JM, Shapira AH (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 58:786-789
8. Corsini GU, Pintus S, Chiueh CC, Weiss JF, Kopin IJ (1985) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. Eur J Pharmacol 119:127-128
9. Corsini GU, Zuddas A, Bonuccelli U, Schinelli S, Kopin IJ (1987) 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol or acetaldehyde. Life Sci 40:827-832
10. Corsini GU, Vaglini F, Fornai F, Saginario A, Zuddas A (1991) (+)MK-801 prevents dopaminergic perikaria damage in MPTP and acetaldehyde-treated mice. Posters in Neuroscience 1:33-36
11. Corsini GU, Vaglini F, Zuddas A, Fornai F, Saginario A, Scalori V (1992) Excitatory amino acids, MPTP toxicity and dopaminergic nerve cell death in Parkinson's disease. In Agid Y, ed. Current trends in the treatment of Parkinson's disease London: John Libbey & Company Ltd, pp. 5-17
12. Di Monte DA, Wu EY, Irwin I, De Lanney LE, Langston JW (1992) Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes. Glia 5:48-55
13. Fornai F, Alessandri' MG, Fascetti F, Vaglini F, Corsini GU (1995) Clonidine suppresses 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine-induced reductions of striatal dopamine and tyrosine-hydroxilase activity in mice. J Neurochem 65:704-709
14. Fornai F, Vaglini F, Maggio R, Bonuccelli U, Corsini GU (1996) Excitatory Amino Acids and MPTP toxicity. In Battistin L, Scarlato G, Caraceni T, Ruggeri S (eds). Advances in Neurology, Vol. 69 Lippincott-Raven Publishers, Philadelphia, pp 167-176
15. Fuller RW, Hemrich-Luecke SK (1985) Effects of amfomelic acid, alpha-methyltyrosine, Ro 4-1284 and haloperidol pretreatment on the depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Res Commun Chem Pathol Pharmacol 48:17-25
16. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK (1991) Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol Exp Ther 257:691-697
17. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK (1994a) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. J Pharmacol Exp Ther 270:1000-1007
18. Giovanni A, Sonsalla PK, Heikkila RE (1994b) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium J Pharmacol Exp Ther 270:1008-1014
19. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984), Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467-469
20. Herkenham MA, Little MD, Bankiewicz K, Yang SC, Markey SP, Johannessen JN (1991) Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40:133-158
21. Irwin I, Langston JW, DeLanney LE (1987a) 4-Phenylpyridine (4PP) and MPTP: The relationship between striatal MPP+ concentrations and neurotoxicity. Life Sci 40:731
22. Irwin I, Wu, EY, DeLanney LE, Trevor L, Langston JW (1987b) The effect of diethyldithiocarbamate on the biodisposition of MPTP: an explanation for enhanced neurotoxicity. Eur J Pharmacol 141:209-217
23. Irwin I, Finnegan KT, DeLanney LE, Di Monte D, Langston JW (1992) The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57B1/6 mice: a critical reassessment. Brain Res 572:224-231
24. Javitch JA, Snyder SH (1985) Uptake of MPP+ by dopamine neurons explains selectivity of Parkinsonism inducing neurotoxin MPTP. Eur J Pharmacol 106:455-456
25. Johannessen JN, Chiueh CC, Burns RS, Markey SP (1985) Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci 36:219-224
26. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980
27. Langston JW, Irwin I, Langston EB, Forno LS (1984) Pargyline prevents MPTP-induced Parkinsonism in primates. Science 225:1480-1482
28. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin Phenol reagent. J Biol Chem 193:265-275
29. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature 311:464-467
30. Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 36:2503-2508
31. Overton P, Clark D (1991) N-methyl-D-aspartate increases the excitability of nigrostriatal dopamine terminals. Eur J Pharmacol 201:117-120
32. Ramsay RR, Singer TP (1986) Energy dependent uptake of N-methyl-4phenylpyridinium the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondria. J Biol Chem 261:7585-7587
33. Riachi NJ, Harik SI, Kalaria RN, Sayre LM (1988) On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity II: Susceptibility among mammalian species correlate with the toxin's metabolic patterns in rat microvessels and liver. J Pharmacol Exp Ther 244:443-448
34. Riachi NJ, Lamanna JC, Harik SI (1989) Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain J Pharmacol Exp Ther 249:744-748
35. Russ H, Gliese M, Sonna J, Shomig E (1992) The extraneuronal transport mechanism for noradrenaline (uptake 2) avidly transports 1-methyl-4phenylpyridinium (MPP+) Naunyn Schmiedebergs Arch Pharmacol 346:158-165
36. Sonsalla PK, Zeevalk GD, Manzino L, Giovanni A, Nicklas WJ (1992) MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J Neurochem 58:1979-1982
37. Turski L, Bressler K, Rettig KJ, Loshmann PA, Wachtel H (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349:414-418
38. Vaglini F, Fascetti F, Fornai F, Maggio R, Corsini GU (1994) (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice. Brain Res 668:194-203
39. Vaglini F, Pardini C, Maggio R, Corsini GU (1995) Role of excitatory amino acids in diethyldithiocarbamate-induced cell death in mesencephalic cell cultures. Brain Res 675:127-132
40. Zuddas A, Corsini GU, Schinelli S, Johannessen JN, di Porzio U, Kopin IJ (1989) MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra. Brain Res 501:1-10
41. Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GU (1992) MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J Neurochem 59:733-739
42. Zuddas A, Fascetti F, Corsini GU, Piccardi MP (1994) In Brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model for natural resistance to MPTP toxicity. Exp Neurol 127:54-61